AEON Biopharma, Inc.
AEON Biopharma is a biopharmaceutical company developing ABP-450, a botulinum toxin complex licensed from Daewoong, as a biosimilar to Botox® for therapeutic indications. Its development program focuses on the FDA’s 351(k) pathway and aims to support U.S. approval across Botox®’s approved therapeutic indications. AEON holds exclusive development and distribution rights for therapeutic uses in the United States, Canada, the European Union, the United Kingdom and certain other international territories. Daewoong manufactures ABP-450 in South Korea. AEON intends to commercialize ABP-450 in the United States for the physician-administered, buy-and-bill therapeutic botulinum toxin market if the product receives regulatory approval. It has never generated revenue from ABP-450. The same toxin is marketed for cosmetic use by Evolus as Jeuveau® in the United States and Nuceiva® in Canada and the European Union.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AEON in the last 30 days.
See all $AEON insider activity →AEON Biopharma amended its two-year milestone warrants, reducing the exercise price to $0.20 per share and $0.1999 per pre-funded warrant. The company expects $6.2 million in gross proceeds from warrant exercises. The amendment applies to all outstanding warrants, expiring November 16, 2026, according to the company.
AEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 2, 2026, AEON Biopharma, Inc. (the “Company”) entered into an Amendment to Two-Year Milestone Warrant to Purchase Common Stock or Pre-Funded Warrants (the “Warrant Amendment”) with holders representing at least 67%
AEON Biopharma plans to develop ABP-450 as a biosimilar to BOTOX®, targeting a Q4 2026 IND submission for a CMAP study. The company aims for full-label access across BOTOX®’s 12 indications, with FDA feedback suggesting supportive evidence from prior studies. ABP-450 is not yet FDA-approved.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AEON (AEON Biopharma, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent AEON coverage spans corporate actions, technology and financial news.
The amendment provides immediate cash inflow and may improve liquidity, but also signals potential dilution.
Lower warrant strike should increase likelihood of exercises before the Nov. 16, 2026 expiration, bringing near-term cash inflow but also dilutive overhang.
The filing signals a new development program that may affect AEON's valuation as the company pursues a 351(k) biosimilar pathway.
The lock‑up may limit supply of shares from insiders, potentially supporting the stock price in the short term.
Target hike points to upside potential.
AlphAI scores every news story that mentions AEON with an AI model for sentiment and relevance, and aggregates insider trades from AEON Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AEON Biopharma amended its two-year milestone warrants, reducing the exercise price to $0.20 per share and $0.1999 per pre-funded warrant. The company expects $6.2 million in gross proceeds from warrant exercises. The amendment applies to all outstanding warrants, expiring November 16, 2026, according to the company.
1 min readAEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 2, 2026, AEON Biopharma, Inc. (the “Company”) entered into an Amendment to Two-Year Milestone Warrant to Purchase Common Stock or Pre-Funded Warrants (the “Warrant Amendment”) with holders representing at least 67%
4 min readAEON Biopharma plans to develop ABP-450 as a biosimilar to BOTOX®, targeting a Q4 2026 IND submission for a CMAP study. The company aims for full-label access across BOTOX®’s 12 indications, with FDA feedback suggesting supportive evidence from prior studies. ABP-450 is not yet FDA-approved.
1 min readAEON Biopharma, Inc. has a lock-up agreement ending on 12-OCT-2026, with a 90-day lock-up period starting 14-JUL-2026. The company, its executives, and certain stockholders are subject to the lock-up, with exceptions for warrant exercises and NYSE American listing compliance. AEON is a clinical-stage biopharmaceutical company focused on developing ABP-450 for medical conditions like migraine and PTSD.
1 min readAnalysts updated price targets for several companies. Citigroup raised HPE's target to $92. Goldman Sachs increased PSX's target to $274. Raymond James cut LQDA's target to $53. Mizuho boosted MU's target to $1,400. Lake Street raised AEON's target to $2. Morgan Stanley lowered AAPL's target to $355. JP Morgan reduced ZION's target to $65. Evercore ISI cut WFC's target to $90. UBS increased DT's target to $74. Guggenheim raised NFLX's target to $80.
2 min readAeon Biopharma's shares rose 19% after the FDA agreed with its study design for ABP-450, a Botox biosimilar. The company plans to submit an investigational new drug application in Q4, with a market cap of $15 million (NYSE: AEON).
1 min readAEON Biopharma received FDA feedback on its biosimilar ABP-450, clarifying the development path. The FDA agreed to consider previous studies as supportive evidence and recommended a pharmacodynamic study. AEON plans to submit an IND for this study in Q4 2026 and aims to streamline development, potentially avoiding a full clinical efficacy study. The company expects to return to the FDA in 2027 with its evidence package.
2 min readTenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.
3 min readAeon Biopharma reported positive results from a stress test comparing its ABP-450 treatment to Botox, showing similar degradation under thermal and oxidative stress. The company plans a multi-lot comparability study. Shares of Aeon were up 1% to 23 cents, with a market cap of $11.8 million.
2 min readOn Friday, notable insider trading activity was reported for several US-listed companies. Global Water Resources (GWRS) directors bought shares, with Jonathan L. Levine acquiring 651,618 shares at $8.85 each. AEON Biopharma (AEON) director Timothy P. Lynch purchased 1.15M shares at $0.2117 each. Cloudflare (NET) president Michelle Zatlyn sold $28.3M worth of shares. Illumina (ILMN) director Keith A. Meister sold $145.56M in shares. InvestingPro analysis provided valuation insights for these comp
3 min read
